Literature DB >> 16276277

Utility values in Singapore Chinese adults with primary open-angle and primary angle-closure glaucoma.

Seang-Mei Saw1, Gus Gazzard, Kah-Guan Au Eong, Francis Oen, Steve Seah.   

Abstract

PURPOSE: To evaluate utility values in Chinese glaucoma patients. PATIENT AND METHODS: Singapore Chinese residents (n = 213) with primary open-angle glaucoma or primary angle-closure glaucoma were recruited from a single tertiary ophthalmic center. Standard face-to-face interviews were conducted to ask about utility values (time trade-off and standard gamble for both death and blindness). Ocular information, including current visual acuity, intraocular pressure, visual field defect, and cup-disc ratio were also obtained.
RESULTS: The mean time trade-off utility value was 0.88 (95% confidence interval 0.85, 0.91), and standard gamble for death and blindness were 0.94 (95% confidence interval 0.93, 0.96) and 0.95 (95% confidence interval 0.93, 0.97), respectively. Only 35.7% of patients were willing to trade time, and 34.3% willing to risk blindness in return for perfect vision. Both primary angle-closure glaucoma and primary open-angle glaucoma patients had similar utility values. After adjusting for age, gender, language spoken, educational level, and diagnosis, patients with better eye visual field PSD > 10 were 2.52 times (95% confidence interval 1.13, 5.61) more willing to trade time. In a multivariate model, the odds ratio of willingness to risk blindness for a complete hypothetical glaucoma cure was 9.88 (95% confidence interval 1.65, 59.23) for patients who had only visited an ophthalmologist 15 years or more ago, and 0.53 (95% confidence interval 0.27, 1.02) for patients who had previous trabeculectomy.
CONCLUSION: Most Chinese glaucoma patients in Singapore are not willing to trade time or risk blindness. Patients with worse visual fields in the better-seeing eye are more willing to trade time; whereas patients who have not seen an ophthalmologist for at least 15 years or who had no history of a previous trabeculectomy are more willing to risk blindness.

Entities:  

Mesh:

Year:  2005        PMID: 16276277     DOI: 10.1097/01.ijg.0000185434.08051.82

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  8 in total

Review 1.  [Value-based medicine for glaucoma].

Authors:  C Hirneiss; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

2.  Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.

Authors:  K G Au Eong; E W Chan; N Luo; S H Wong; N W H Tan; T H Lim; A M Wagle
Journal:  Eye (Lond)       Date:  2012-01-06       Impact factor: 3.775

3.  Utility Index and Patient-Reported Outcome Measures in Glaucomatous Patients Comparing with Normal Participants.

Authors:  Kulawan Rojananuangnit; Nuttawan Sudjinda
Journal:  Clin Ophthalmol       Date:  2021-02-25

4.  Does the type of treatment have an influence on utility values in a glaucoma population?

Authors:  Ricardo Augusto Paletta Guedes; Vanessa Maria Paletta Guedes; Sirley Maria Freitas; Alfredo Chaoubah
Journal:  Clin Ophthalmol       Date:  2015-09-07

5.  Utility values for glaucoma patients in Korea.

Authors:  Seulggie Choi; Jin A Choi; Jin Woo Kwon; Sang Min Park; Donghyun Jee
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

6.  Utility values for age-related macular degeneration patients in Korea.

Authors:  Seulggie Choi; Sang Min Park; Donghyun Jee
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

7.  Utility values for glaucoma in Brazil and their correlation with visual function.

Authors:  Ricardo Augusto Paletta Guedes; Vanessa Maria Paletta Guedes; Sirley Maria Freitas; Alfredo Chaoubah
Journal:  Clin Ophthalmol       Date:  2014-03-12

8.  Vision Health-Related Quality of Life in Chinese Glaucoma Patients.

Authors:  Lei Zuo; Haidong Zou; Jianhong Zhang; Xinfeng Fei; Xun Xu
Journal:  J Ophthalmol       Date:  2015-10-07       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.